《盈利預喜》先聲藥業(02096.HK)預計全年利潤倍增至14.8-15.4億人民幣

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

《盈利預喜》先聲藥業(02096.HK)預計全年利潤倍增至14.8-15.4億人民幣

阿思達克 02-22 03:32

先聲藥業(02096.HK)發盈喜，預計2021年度歸屬股東利潤介乎14.8-15.4億人民幣，較2020年度增長121%-130%。主要由於2020年7月上市的原研一類創新藥先必新收入快速增長；出售Simgene Group全部股權錄得收益；及集團持有的投資組合公允價值變動推高投資收益。

先聲藥業(02096.HK)

Relevant Stocks

先聲藥業(02096.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

《盈利預喜》先聲藥業(02096.HK)預計全年利潤倍增至14.8-15.4億人民幣

Services

About Us

Agreement Statement